In this article, we discuss the 7 Best Lab-Grown Meat Stocks to Invest In.
The global cellular agriculture landscape presents a sharp contrast between commercial, fine-dining breakthroughs on the coasts and intensifying regulatory battles across the domestic heartland. Structurally, the global cultured meat market is entering a pivotal inflection point, with industry projections issued this month estimating its valuation at $123.3 million, on a trajectory to expand to $2.5 billion by 2035. This economic momentum is being propelled by rapid technological shifts away from purely minced or ground meat analogs toward sophisticated, 3D tissue-engineered structured products, whole-muscle cuts, and high-margin hybrid foods that blend cultivated animal fats with plant-based scaffolding.
READ ALSO: Michael Burry Stock Portfolio: Top 8 Stock Picks in 2026 and Graham Stephan Stock Portfolio: Top 11 Stocks.
The commercial vanguard of the industry was highlighted earlier this week when celebrity chef and sustainability advocate José Andrés announced the official Washington DC debut of Wildtype’s cell-cultivated salmon at his high-end cocktail bar, Barmini. This strategic activation underscores a growing food service trend where premier culinary figures serve as the primary commercial gatekeepers, normalizing lab-grown seafood and poultry for mainstream consumers through experiential, curated tasting events. Conversely, the domestic political landscape reflects deep friction. Despite regional blockades, the broader sector is maintaining strong momentum, buoyed by expanding Asian food-security investments and ongoing constitutional challenges against state-level bans.
Our Methodology
For this article, we selected food stocks that offer lab-grown or alternative meat products. Data for the hedge fund sentiment surrounding each stock was taken from Insider Monkey’s Q1 2026 database of 1041 elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
Best Lab-Grown Meat Stocks to Invest In
7. Steakholder Foods Ltd. (NASDAQ:STKH)
Steakholder Foods Ltd. (NASDAQ:STKH) focuses on advanced 3D bioprinting technology to create structured, cultured meat products. Rather than just brewing unstructured biomass, the company specializes in proprietary bioprinting hardware and bio-inks designed to mimic the exact marbling, texture, and vascular structures of whole-muscle cuts like beef steaks and seafood fillets. Recently, the company shifted its primary business model toward a business-to-business (B2B) licensing approach. By providing their industrial-scale 3D printers and high-fidelity plant-based or hybrid cell-derived media to global food manufacturers, the firm is positioning itself as a foundational software and hardware infrastructure provider for the entire alternative protein ecosystem. This eliminates the heavy capital expenditure required for standalone meat production.
The broader fundamental bull case for Steakholder Foods Ltd. (NASDAQ:STKH) hinges on this strategic asset-light pivot toward commercializing commercial printers and bio-inks. Moving away from highly capital-intensive, in-house cellular cultivation scales down near-term operational risk and extends cash runway. By locking in strategic B2B supply agreements with major international food processors and alternative protein brands, the company can generate high-margin, recurring software and material revenue streams. Their highly flexible bioprinting technology can easily adapt to evolving local regulatory frameworks, giving them a scalable first-mover advantage as commercial approval paths clear globally.
6. Tyson Foods, Inc. (NYSE:TSN)
Tyson Foods, Inc. (NYSE:TSN) is one of the world’s largest traditional meat processors and has integrated cultured meat and alternative proteins directly into its long-term corporate growth strategy via its venture capital arm, Tyson Ventures. The company was an early strategic investor in major cell-cultivated industry pioneers like UPSIDE Foods and Future Meat Technologies. By backing them during early development, Tyson secured an invaluable front-row seat to the scaling of cellular bioreactor technology. The company is leveraging its unparalleled global supply chain, industrial cold-storage network, and existing distribution channels to eventually deploy these hybrid and cultured products at a commercial scale. This hybrid approach allows the legacy giant to actively future-proof its business against long-term resource scarcity, climate targets, and shifting consumer demographics.
Tyson Foods, Inc. (NYSE:TSN) has flawless operational execution, highlighted in the Q1 2026 earnings report. The firm pulled in Q1 revenue of $13.65 billion, representing a 4.43% year-over-year expansion that crushed Wall Street expectations. The primary fundamental driver was the operational turnaround and margin recovery within the core chicken and pork segments, which benefited from falling grain input costs and disciplined supply-chain optimization. With operating income bouncing back sharply, the firm provides investors unmatched cash flows from legacy proteins alongside embedded upside from its strategic alternative venture portfolio.
5. Beyond Meat, Inc. (NASDAQ:BYND)
Beyond Meat, Inc. (NASDAQ:BYND) has historically dominated the plant-based protein space, but the company is increasingly examining the intersection of plant-based scaffolding and cellular agriculture. As the industry evolves, the development of hybrid meats, which blend texturized plant proteins with real, cell-cultivated animal fat, represents a possible avenue for the firm to elevate flavor and sensory profiles. While maintaining a commitment to vegan-friendly infrastructure, the existing high-capacity manufacturing facilities and global retail and foodservice footprint position Beyond as a commercialization partner for cellular startups.
Beyond Meat, Inc. (NASDAQ:BYND) recently posted earnings for the first quarter of 2026. The company reported net revenue of $58.2 million, and while the top line reflected category headwinds, there were operational improvements. For example, gross margins turned positive to 3.4%, a reversal from negative margins last year. Quarterly operating expenses plummeted 24.9% to $43.1 million, and net losses were slashed in half to $28.5 million. Most importantly, cash consumption dropped to just $11.8 million, proving the firm has successfully emerged from its most intensive cash-burn phase. This lean framework positions the company to achieve profitability as its newly launched functional beverage lines scale up.
4. Pluri Inc. (NASDAQ:PLUR)
Pluri Inc. (NASDAQ:PLUR), through the highly publicized joint venture, Ever After Foods, utilizes proprietary, state-of-the-art 3D bioreactor systems to cultivate animal cells with unprecedented density and cost efficiency. While most cell-cultured companies struggle with the cost of scaling beyond small pilot batches, Pluri’s industrial platform delivers up to a 700% increase in cell production volume compared to conventional methods. This highly specialized technology enables the creation of complex, structured tissues using significantly less expensive growth media. This operational advantage solves the primary hurdle that has long prevented cultured meat from achieving price parity with traditional livestock, transforming Pluri into an essential manufacturing backbone for the global cellular sector.
In the latest earnings report, Pluri Inc. (NASDAQ:PLUR) posted losses per share of $0.55, outperforming Wall Street consensus analyst expectations of losses per share of 0.66 by 16.67%. This marks an operational improvement compared to the losses per share of $0.94 reported in the same prior-year quarter. The firm’s multi-pronged commercial strategy spans highly lucrative sectors outside of food technology, including clinical-grade contract development and manufacturing organization services and high-margin cell therapies. Pluri offers investors a resilient, diversified biotech engine built to capture upside as cellular demand accelerates.
While we acknowledge the potential of PLUR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than PLUR and that has 100x upside potential, check out our report about the cheapest AI stock.
Click to continue reading and see 3 Best Lab-Grown Meat Stocks to Invest In.
READ NEXT: Growth Stock Portfolio: 12 Stock Picks by Carl C. Icahn and Chris Rokos Stock Portfolio: Top 10 Stock Picks.
Disclosure: None. Follow Insider Monkey on Google News.
